| 干扰素α联合亚砷酸治疗JAK2V617F突变阳性真性红细胞增多症和原发性血小板增多症的疗效 |
| |
| 引用本文： | 雷林子,王耀美,刘玉章,刘丽娜,房佰俊.干扰素α联合亚砷酸治疗JAK2V617F突变阳性真性红细胞增多症和原发性血小板增多症的疗效[J].现代肿瘤医学,2022,0(6):1072-1075. |
| |
| 作者姓名： | 雷林子 王耀美 刘玉章 刘丽娜 房佰俊 |
| |
| 作者单位： | 郑州大学附属肿瘤医院、河南省肿瘤医院血液科，河南 郑州 450008 |
| |
| 基金项目： | 国家自然科学基金资助项目(编号:81900108);中原英才计划基金资助项目(编号:214200510023)。 |
| |
| 摘 要： | 目的:观察干扰素α（interferon-α，IFN-α）联合亚砷酸治疗JAK2V617F突变阳性的真性红细胞增多症（polycythemia vera，PV）和原发性血小板增多症（essential thrombocythemia，ET）患者的有效性及安全性。方法:回顾性分析2015年12月至2021年01月在我院血液科收治的44例PV和ET患者的临床资料，比较IFN-α联合亚砷酸（观察组）以及单用IFN-α（对照组）的疗效及不良反应。结果:观察组血液学总有效率（overall response rate，ORR）为88.5%，高于对照组。至随访截止时，观察组达血液学及分子生物学缓解的ORR均高于对照组。并且观察组并未出现不良反应发生率增加的情况。结论:亚砷酸能加速并增强IFN-α抗肿瘤作用，二者联合治疗能提高JAK2V617F突变阳性的PV和ET的临床缓解率和疗效持续时间，且安全性高。
|
| 关 键 词： | 真性红细胞增多症 原发性血小板增多症 干扰素α 亚砷酸 疗效 |
Efficacy of interferon-α combined with arsenite in the treatment of JAK2V617F mutation-positive polycythemia vera and essential thrombocythemia |
| |
| LEI Linzi,WANG Yaomei,LIU Yuzhang,LIU Lina,FANG Baijun.Efficacy of interferon-α combined with arsenite in the treatment of JAK2V617F mutation-positive polycythemia vera and essential thrombocythemia[J].Journal of Modern Oncology,2022,0(6):1072-1075. |
| |
| Authors: | LEI Linzi WANG Yaomei LIU Yuzhang LIU Lina FANG Baijun |
| |
| Affiliation: | Department of Hematology,the Affiliated Cancer Hospital of Zhengzhou University,Henan Cancer Hospital,Henan Zhengzhou 450008,China. |
| |
| Abstract: | Objective:To observe the efficacy and safety of interferon-α(IFN-α)combined with arsenite in the treatment of JAK2V617Fmutation-positive patients with polycythemia vera(PV)and essential thrombocythemia(ET).Methods:The clinical data of 44 patients with PV and ET in department of hematology in our hospital from December 2015 to January 2021 were retrospectively analyzed,and the efficacy and adverse reactions of IFN-αcombined with arsenite(observation group)and IFN-αalone(control group)were compared.Results:The hematological overall response rate(ORR)of observation group was 88.5%,which was higher than that of control group.By the end of follow-up,the ORR of hematology and molecular biology remission in observation group was higher than that of control group.And there were no serious adverse reactions during the treatment in observation group.Conclusion:Arsenite can accelerate and enhance the anti-tumor effect of IFN-α,and the combination of the two therapies can improve the clinical remission rate and duration of efficacy of JAK2V617Fmutation-positive PV and ET,with high safety. |
| |
| Keywords: | polycythemia vera essential thrombocythemia interferon-α arsenite clinical efficacy |
| 本文献已被 维普 等数据库收录！ |
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载全文 |
